Rosai–Dorfman disease of the central nervous system: A clinical, radiological, and prognostic study of 12 cases

Xingshu Zhang, Wen Yin, Youwei Guo, Yi He, Zhipeng Jiang, Yuzhe Li, Bo Xie, Seng Zhang, Xingjun Jiang, Qing Liu, Jian YuanFrontiers in Oncology 2022 · DOI

TL;DR

This study investigates Rosai-Dorfman Disease (RDD) affecting the central nervous system (CNS), a rare condition that often mimics more common brain tumors like meningiomas. The researchers highlight key imaging features that can help distinguish CNS-RDD and emphasize the importance of surgical resection, with chemotherapy and steroids showing promise for managing relapsed or residual cases.

What Problem Does This Paper Address?

Rosai-Dorfman Disease (RDD) is a benign histiocytic proliferative disorder. While typically affecting lymph nodes, it can rarely involve the central nervous system (CNS-RDD). This CNS involvement presents a significant diagnostic challenge due to its atypical clinical and radiological presentation, often leading to misdiagnosis as meningioma. Furthermore, there's a lack of standardized treatment guidelines for CNS-RDD. This paper aims to shed light on the clinical, radiological, and prognostic aspects of CNS-RDD by analyzing a cohort of 12 patients, hoping to improve diagnostic accuracy and inform treatment strategies.

Methods

This was a retrospective study analyzing clinical data, imaging findings (conventional brain MRI with T1-weighted, T2-weighted, and contrast-enhanced T1-weighted sequences), and pathological results from 12 patients diagnosed with CNS-RDD at Xiangya Hospital between January 2012 and June 2022. The researchers focused on summarizing imaging characteristics, evaluating surgical resection extent, and assessing patient outcomes through follow-up. Immunohistochemistry was used to confirm the diagnosis, looking for positive S100 and CD68 expression, and negative CD1a.

Datasets

The study utilized data from 12 patients diagnosed with CNS-RDD at a single institution (Xiangya Hospital). No new benchmarks or publicly available datasets were introduced.

Key Insights and Ideas

  • Mimicking Meningioma: CNS-RDD frequently presents as dura-based masses with homogeneous enhancement, making it easily mistaken for meningioma on initial imaging. This highlights the need for a high index of suspicion.
  • Subtle Imaging Clues: While challenging, certain MRI features can point towards CNS-RDD. The "lobulation and/or pseudopodium sign" – where the lesion margin is irregular or the meninges extend into the brain – is a significant indicator. Multiple intracranial lesions also raise suspicion.
  • Diverse Presentations: CNS-RDD can manifest in various locations, including the cerebral convexity, skull base, brainstem, and even the spinal cord, leading to a wide range of symptoms from headaches and seizures to neurological deficits.
  • Surgery as a Primary Treatment: Surgical resection is presented as the primary and effective treatment for CNS-RDD, with total resection offering the best prognosis and a low recurrence rate.
  • Adjuvant Therapies for Recurrence: For relapsed or residual CNS-RDD, a combination of chemotherapy (e.g., cytarabine, lenalidomide) and steroid therapy demonstrated promising therapeutic efficacy, leading to complete remission in some cases.

Key Results

  • Patient Demographics: The study included 12 patients (9 male, 3 female) with an average age of 41 years (range 12-67).
  • Tumor Locations: The most common locations were the cerebral convexity and skull base (9 patients), with two cases of intraparenchymal RDD and one spinal cord lesion.
  • Surgical Outcomes: Seven patients underwent total resection, three subtotal resection, one partial resection, and one stereotactic biopsy. Of the seven with total resection, six showed no recurrence during follow-up.
  • Treatment Efficacy: One patient with a relapsed lesion and another with residual disease showed complete remission after combination chemotherapy and steroid therapy.
  • Prognosis: The mean follow-up time was 50 months. One patient died due to kidney failure and pulmonary infection post-surgery. Another patient experienced disease progression despite steroid therapy.

Limitations and Future Work

The authors acknowledge several limitations:

  • Retrospective Design: The study's retrospective nature limits the ability to establish definitive cause-and-effect relationships.
  • Small Sample Size: CNS-RDD is rare, resulting in a small cohort (12 patients), which limits the generalizability of the findings.
  • Incomplete Systemic Imaging: Some patients did not undergo whole-body imaging, potentially missing latent lesions in other systems.

Future work should focus on prospective studies with larger, multi-center cohorts to further elucidate the pathogenesis, refine diagnostic criteria, and establish standardized treatment protocols for CNS-RDD.

Summary updated

Abstract

CNS-RDD, as a rare disease, presents a significant diagnostic challenge for clinicians. Solitary CNS-RDD are easily misdiagnosed as meningioma. However, when the MRI imaging of the disease represents dura-based masses with significant edema, homogeneous enhancement, lobulation, and/or pseudopodium sign, we should consider it might be the CNS-RDD. Surgery is an important and effective therapy for CNS-RDD. Steroids and chemotherapy are safe and effective for the postoperative treatment of relapsing cases or residual lesions.
BibTeX
@inproceedings{zhang2022rosaidorfman,
  author = {Xingshu Zhang and Wen Yin and Youwei Guo and Yi He and Zhipeng Jiang and Yuzhe Li and Bo Xie and Seng Zhang and Xingjun Jiang and Qing Liu and Jian Yuan},
  title = {{Rosai–Dorfman disease of the central nervous system: A clinical, radiological, and prognostic study of 12 cases}},
  booktitle = {Frontiers in Oncology},
  year = {2022},
  doi = {10.3389/fonc.2022.1013419},
}
Figure